In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brexit, Brexit Everywhere And Such A Lot To Think

Executive Summary

For medtech manufacturers working in the EU market, the biggest regulatory changes for a generation are on the cusp of coming into force – at last. Or does this spell double trouble for UK manufacturers, who are rightly nervous about how Brexit will alter their business?

You may also be interested in...



UK MHRA Presses For Leading Global Role Post-Brexit

The UK MHRA believes it has a valid and vital role to play on the global regulatory stage even after the UK leaves the EU.

On-Prescription Apps Are Just One Vital Part Of Germany’s Digital Strategy

Are too few digital health care apps approved for reimbursement in Germany? That’s not the point, says the health care ministry, urging a look at the bigger strategic picture.

Swiss Parliament’s Vote For Medtech Innovation Succeeds

Another key stage has been reached in Switzerland’s bid to enable US FDA-approved medtech to be used in the local population.

Topics

Latest News
See All
UsernamePublicRestriction

Register

IV004940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel